Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ESC 25: The REBOOT-CNIC Trial
Author(s): Borja Ibanez Added: 9 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy… View more

MI/ACS

Heart Failure
Beta-Blockers Post-MI Show No Benefit in Preserved LVEF
Added: 3 months ago Source:  Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis… View more

MI/ACS

Heart Failure
Job title: Nephrology and Hypertension Specialist
Dr Erika Jones is Associate Professor in the Division of Nephrology and Hypertension at the University of Cape Town and Groote Schuur Hospital in Cape Town, SA.Dr Jones interests areparticularly in hypertension, having done her PhDin this area.One of the aspects of hypertension that she is studying currently and which is of major concern to nephrologists in Cape Town, is the rising incidence of… View more
HFA 2026: Survival in Middle-Aged and Older Patients With Advanced HF
Author(s): Nir Uriel Added: 3 weeks ago
HFA Congress 2026 — Dr Nir Uriel (NewYork-Presbyterian, New York, US) discusses findings from a comparative analysis evaluating survival outcomes in middle-aged and older patients with advanced heart failure treated with left ventricular assist device (LVAD) therapy or heart transplantation.Drawing on two prospectively collected data sets: the Momentum 3 trial (HeartMate 3) and the UNOS… View more

Heart Failure
Polygenic Risk Score Independently Predicts New-Onset Heart Failure
Added: 8 months ago Source:  Radcliffe Cardiology, Mirjam Boros
The global burden of heart failure (HF) remains a significant challenge for healthcare systems.² While clinical risk factors are well-established, the utility of genetic information in predicting incident HF has been less certain. A recent study investigated the ability of a heart failure polygenic risk score (HF PRS) to predict new-onset HF in individuals across the full spectrum of… View more

Imaging & Diagnostics

Prevention & Chronic Conditions
Author(s): Julian Gillmore , Margot K Davis , Ahmad Masri , et al Added: 1 year ago
First presented at ESC 2024, this on-demand programme sees Prof Julian Gillmore (University College London, London, UK) lead a distinguished faculty compromising of Dr Ahmad Masri (Oregon Health & Science University Medical Group, Portland, US), Dr Margot Davis (University of British Columbia, Vancouver, CA), and Dr Giuseppe Vergaro (Sant’Anna, Pisa, IT).The faculty present recent epidemiological… View more

Heart Failure
EMPA-KIDNEY: Empagliflozin in Patients with Chronic Kidney Disease
Author(s): William Herrington Added: 1 year ago
Long-term cardio-renal outcomes investigating empagliflozin (Boehringer Ingelheim) on kidney disease progression (KDP) or cardiovascular death in patients with pre-existing chronic kidney disease.In this short interview, Prof William Herrington (Nuffield Department of Population Health, University of Oxford, Oxford, UK) discusses the findings from EMPA-KIDNEY (NCT03594110).EMPA-KIDNEY is an… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
ESC HFA 25: SCD-PROTECT
Author(s): Johann Bauersachs Added: 1 year ago
ESC HF 25 - SCD-PROTECT shows high risk of sudden cardiac arrest (SCA) and sudden cardiac death (SCD) during early medical therapy optimization for reduced LVEF in patients with new non-ischemic cardiomyopathy or MI/CAD.Prof Johann Bauersachs (Hannover Medical School, Hannover, DE) discusses findings from the SCD–PROTECT study, an investigation of sudden cardiac arrest in patients with newly… View more

MI/ACS

Heart Failure
STEP: Early Intensive BP Control Shows Long-Term Benefit
Added: 7 months ago Source:  Radcliffe Cardiology
New long-term data from the Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients (STEP) trial suggests that sustained, intensive blood pressure (BP) control provides greater cardiovascular benefits compared to a delayed approach in older patients with hypertension.¹ The findings also indicate that the earlier intensive treatment is initiated, the greater the reduction in… View more

Demographic

Heart Failure
ACC 26: SURPASS-CVOT - Tirzepatide vs Dulaglutide in T2D
Author(s): Steven E Nissen Added: 2 months ago
American College of Cardiology Congress 2026 – Dr Steven Nissen (Cleveland Clinic, Cleveland, OH, US) joins us to discuss the effects of tirzepatide compared with dulaglutide on expanded cardiorenal outcomes from the SURPASS-CVOT trial (NCT04255433; Eli Lilly and Company).This international, double-blind, randomised, phase III cardiovascular outcomes trial enrolled 13,299 patients aged 40 and… View more

Cardiovascular Kidney Metabolic

Heart Failure